About
Looking for more information?
Contact our responsive and friendly client services team any time.
INVESTOR PRESENTATION - BOTANIX PHARMACEUTICALS LTD
BOTANIX PHARMACEUTICALS LTD
Health Care
Botanix Pharma aims to develop next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.
Read moreMarket Cap
94.35m
Price at Close
$0.097
4w avg. Volume
7.16m
4w avg. Turnover
$712.82k
Announcements
| announcement | t+2 movement | date |
|---|---|---|
| - | 21 Oct 2020 |
| - | 21 Oct 2020 |
| +10.00% | 12 Oct 2020 |
| -9.00% | 29 Sep 2020 |
| -1.79% | 07 Sep 2020 |
| -1.79% | 07 Sep 2020 |
| +2.08% | 31 Aug 2020 |
| +2.08% | 31 Aug 2020 |
| -5.45% | 11 Aug 2020 |
| +1.96% | 29 Jul 2020 |
Market Data
Current Price
$0.097
52WK HIGH
$0.14
52WK LOW
$0.023
1YR RETURN
-22.40%
1YR RETURN VS. SECTOR
-45.85%
90 DAY RETURN
+76.36%
ASX RANK
816
/2,010
SECTOR RANK
16
/47
SHARES OUTSTANDING
972.70m
BOTANIX PHARMACEUTICALS LTD
Health Care
Botanix Pharma aims to develop next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.
Read moreMarket Cap
94.35m
Price at Close
$0.097
4w avg. Volume
7.16m
4w avg. Turnover
$712.82k
ASX:BOT is not raising right now
Want to invest?
Contact Us
(03) 9028 2888
clients@freshequities.com
Address
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia